T Jonathan Yang1, Jung Hun Oh2, Michael R Folkert1, Gaorav Gupta1, Weiji Shi3, Zhigang Zhang3, Aki Morikawa4, Andrew Seidman4, Cameron Brennan5, Yoshiya Yamada1, Timothy A Chan1, Kathryn Beal6. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: BealK@MSKCC.org.
Abstract
BACKGROUND: With the continuing increase in the use of definitive stereotactic radiosurgery (SRS) for patients with limited brain metastases (BM), clinicians need more specific prognostic tools. We investigated clinical predictors of outcomes in patients with limited breast cancer BM treated with SRS alone. METHODS AND MATERIALS: We identified 136 patients with breast cancer and 1-3 BM who underwent definitive SRS for 186 BM between 2000 and 2012. The Kaplan-Meier method was used to assess overall survival (OS), regional failure (RF), and local failure (LF). Associations between clinical factors and outcomes were tested using Cox regression. A point scoring system was used to stratify patients based on OS, and the predictive power was tested with concordance probability estimate (CPE). RESULTS: The median OS was 17.6 months. The 12-month RF and LF rates were 45% and 10%, respectively. On multivariate analysis, >1 lesion (hazard ratio [HR] = 1.6, P=.02), triple-negative (TN) disease (HR=2.0, P=.006), and active extracranial disease (ED) (HR=2.7, P<.0001) were significantly associated with worse OS. The point score system was defined using proportional simplification of the multivariate Cox proportional hazards regression function. The median OS for patients with 3.0-4.0 points (n=37), 4.5-5.5 points (n=28), 6.0-6.5 points (n=37), and 8-8.5 points (n=34) were 9.2, 15.6, 25.1, and 45.1 months, respectively (P<.0001, CPE = 0.72). Active ED (HR=2.4, P=.0007) was significantly associated with RF. Higher risk for LF was significantly associated with larger BM size (HR=3.1, P=.0001). CONCLUSION: Patients with >1 BM, active ED, and TN had the highest risk of death after SRS. Active ED is an important prognostic factor for OS and intracranial control.
BACKGROUND: With the continuing increase in the use of definitive stereotactic radiosurgery (SRS) for patients with limited brain metastases (BM), clinicians need more specific prognostic tools. We investigated clinical predictors of outcomes in patients with limited breast cancer BM treated with SRS alone. METHODS AND MATERIALS: We identified 136 patients with breast cancer and 1-3 BM who underwent definitive SRS for 186 BM between 2000 and 2012. The Kaplan-Meier method was used to assess overall survival (OS), regional failure (RF), and local failure (LF). Associations between clinical factors and outcomes were tested using Cox regression. A point scoring system was used to stratify patients based on OS, and the predictive power was tested with concordance probability estimate (CPE). RESULTS: The median OS was 17.6 months. The 12-month RF and LF rates were 45% and 10%, respectively. On multivariate analysis, >1 lesion (hazard ratio [HR] = 1.6, P=.02), triple-negative (TN) disease (HR=2.0, P=.006), and active extracranial disease (ED) (HR=2.7, P<.0001) were significantly associated with worse OS. The point score system was defined using proportional simplification of the multivariate Cox proportional hazards regression function. The median OS for patients with 3.0-4.0 points (n=37), 4.5-5.5 points (n=28), 6.0-6.5 points (n=37), and 8-8.5 points (n=34) were 9.2, 15.6, 25.1, and 45.1 months, respectively (P<.0001, CPE = 0.72). Active ED (HR=2.4, P=.0007) was significantly associated with RF. Higher risk for LF was significantly associated with larger BM size (HR=3.1, P=.0001). CONCLUSION:Patients with >1 BM, active ED, and TN had the highest risk of death after SRS. Active ED is an important prognostic factor for OS and intracranial control.
Authors: Cameron Brennan; T Jonathan Yang; Patrick Hilden; Zhigang Zhang; Kelvin Chan; Yoshiya Yamada; Timothy A Chan; Stella C Lymberis; Ashwatha Narayana; Viviane Tabar; Philip H Gutin; Åse Ballangrud; Eric Lis; Kathryn Beal Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-01 Impact factor: 7.038
Authors: Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Johanna C Bendell; Susan M Domchek; Harold J Burstein; Lyndsay Harris; Jerry Younger; Irene Kuter; Craig Bunnell; Montse Rue; Rebecca Gelman; Eric Winer Journal: Cancer Date: 2003-06-15 Impact factor: 6.860
Authors: Serap Akyurek; Eric L Chang; Anita Mahajan; Samuel J Hassenbusch; Pamela K Allen; Leni A Mathews; Almon S Shiu; Moshe H Maor; Shiao Y Woo Journal: Am J Clin Oncol Date: 2007-06 Impact factor: 2.339
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Priscilla K Stumpf; Diana M Cittelly; Tyler P Robin; Julie A Carlson; Kelly A Stuhr; Maria Jose Contreras-Zarate; Steven Lai; D Ryan Ormond; Chad G Rusthoven; Laurie E Gaspar; Rachel Rabinovitch; Brian D Kavanagh; Arthur Liu; Jennifer R Diamond; Peter Kabos; Christine M Fisher Journal: Clin Cancer Res Date: 2019-04-02 Impact factor: 12.531
Authors: Aki Morikawa; Lilly Jordan; Raquel Rozner; Sujata Patil; Adrienne Boire; Elena Pentsova; Andrew D Seidman Journal: Clin Breast Cancer Date: 2016-07-25 Impact factor: 3.225
Authors: Matthew N Mills; Chetna Thawani; Nicholas B Figura; Daniel E Oliver; Aixa E Soyano; Arnold Etame; Timothy J Robinson; James K Liu; Michael A Vogelbaum; Peter A Forsyth; Brian J Czerniecki; Hatem H Soliman; Hyo S Han; Hsiang-Hsuan Michael Yu; Kamran A Ahmed Journal: J Neurooncol Date: 2021-03-19 Impact factor: 4.130
Authors: Daniel Gorovets; Paul Rava; Daniel K Ebner; David J Tybor; Deus Cielo; Yakub Puthawala; Timothy J Kinsella; Thomas A DiPetrillo; David E Wazer; Jaroslaw T Hepel Journal: Front Oncol Date: 2015-05-11 Impact factor: 6.244
Authors: Andrew Keller; Rahim Ismail; Peter S Potrebko; Julie Pepe; Meiling Wu; Kunal Saigal; Matthew Biagioli; Ravi Shridhar; Robert Holloway; Melvin Field; Nikhil G Rao Journal: Cureus Date: 2016-12-31
Authors: Kevin Armstrong; Jennifer Ward; Mary Dunne; Luke Rock; Jennifer Westrup; Christopher R Mascott; Pierre Thirion; Alina Mihaela Mihai Journal: Front Oncol Date: 2019-05-28 Impact factor: 6.244
Authors: Ignacio Morales-Orue; Juan Zafra-Martin; Laura Garcia; Rodolfo Chicas-Sett; Juan Castilla-Martinez; Maria Auxiliadora Cabezon; Javier Burgos; Marta Lloret; Pedro C Lara Journal: Transl Cancer Res Date: 2020-01 Impact factor: 1.241